


Now ideas for wellness

From June 2021, the Meiji Group adopted a renewed Group Slogan, “Now ideas for wellness”. The Meiji Group has been trying to spread the world of Tastiness, Enjoyment, Health and Reassurance for more than 100 years. We will integrate the food and pharmaceutical expertise we have accumulated both inside and outside our Group to create cutting-edge value. We will focus on health and play an integral role in the health field.



Consolidated Performance and Share Price in Recent Years

*After applying revenue recognition standards



Major Shareholders


(as of March 31, 2022)

	Number of shares held (Thousands)	Percentage of total shares issued (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)	24,170	16.29
Custody Bank of Japan, Ltd. (Trust Account)	7,034	4.74
Nippon Life Insurance Company	3,348	2.25
The Norinchukin Bank	2,892	1.94
Meiji Holdings Employee Shareholding Association	2,669	1.79
Meiji Holdings Trading-Partner Shareholding Association	2,654	1.78
STATE STREET BANK WEST CLIENT - TREATY 505234	2,521	1.69
Mizuho Bank, Ltd.	2,417	1.62
Resona Bank, Limited	2,117	1.42
JP MORGAN CHASE BANK 385781	1,708	1.15

* In addition to the above-mentioned shares, the Company owns 7,548 thousands shares of treasury stock (a 5.08% shareholding).

Shareholding by Type of Shareholder

(as of March 31, 2022)



Financial Institutions	39.02%
Individuals and Others	27.18%
Foreign Companies, etc.	21.99%
Other Companies	9.66%
Financial Instruments Dealers	2.15%

* "Individuals and Others" includes treasury stock.

External Recognition

Member of **Dow Jones Sustainability Indices**
Powered by the S&P Global CSA

ACCESS TO **NUTRITION INDEX™**



Corporate Governance (as of June 29, 2022)

Company with audit & supervisory board members

Directors:	9
Independent outside directors	4 (44.4%)
Women	2 (22.2%)

Inquiries

IR Team, Corporate Communication Dept.,
Meiji Holdings Co., Ltd.

✉ E-mail ir-info@meiji.com

🌐 Web <https://www.meiji.com/global/investors/>


2023 Medium-term Business Plan (FYE March 2022-2024)

Concept 「Promote the Meiji ROESG®* Management effectively」
 Realize both profit growth and sustainability activities

- Key Issues**
- Business strategy
 - Food segment
 - Recover from the slump in our core business
 - Accelerate growth in our business overseas
 - Pharmaceutical segment
 - Strengthen vaccine business
 - Expand CMO/CDMO business
 - Overall group
 - Venture into new fields
 - Improve business management using ROIC effectively
 - Investing to grow business while constructing strong financial base
 - Promote the Meiji Group Sustainability 2026 Vision

Financial strategy

- Apply ROIC towards strengthening our business management structure and improving capital productivity.
- Reduce cross-shareholding by 30% (based on book value).



Find out more about The Meiji ROESG®
<https://www.meiji.com/global/investors/business-plans/mid-term-plan/>

The Meiji ROESG®

ROE


Achieve ESG goals

Indicators unique to Meiji




Food Segment

Net Sales / Operating Profit



Breakdown of Sales*



Overseas business

[Main products]

- CHINA
 - Yogurt
 - Chilled milk
 - Sports protein
 - Chocolate
 - Ice cream



- ASIA
 - Chocolate snacks
 - Infant formula



- US
 - Chocolate snacks
 - Biscuits



Market Share of Main Products


Yogurt
 Share **38.6%** [No.1]
 Market size JPY458.8 bn
 Source: INTAGE SRI+, Yogurt Market Share in Value from April 2021 to March 2022

Powdered & Granulated protein
 Share **34.3%** [No.1]
 Market size: JPY63.5 bn
 Based on Meiji data as of FYE March 2022


Chocolate
 Share **24.8%** [No.1]
 Market size: JPY413.7 bn
 Source: INTAGE SRI, Chocolate Market Share in Value from April 2021 to March 2022

Pharmaceutical Segment

Net Sales · Operating Profit



Breakdown of Sales*



Overseas business

[Main products]

- MEIACT (an antibacterial drug)
- ADANT (a treatment for reducing arthritic pain in the joints)



[Production sites]
 In China, Thailand, India, Indonesia and Spain

Market Share of Main Products

Copyright©2022 IQVIA
 Source: Calculated based on JPM 2022 Mar. MAT Market scope as defined by Meiji Seika Pharma
 *Reprinted with permission



Systemic antibacterial drugs
 Share **19.4%** [No.1]
 Market size: JPY148.5 bn



Influenza Vaccine
 Share **35.5%** [No.1]
 Market size: JPY76.9 bn

* After applying revenue recognition standards